top of page
Follow the Remedy Plan story with our most recent media hits and press releases. Contact [email protected] for interview requests.
Media
Media
Follow the Remedy Plan story with our most recent media hits and press releases. Contact [email protected] for interview requests.
December 4, 2025
Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
November 12, 2025
Remedy Plan Therapeutics Advances RPT1G for Myeloid Cancer Patients with Phase 1 Safety Data and IND Approval
May 13, 2025
Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials
December 18, 2024
Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor
December 10, 2024
UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting
November 5, 2024
Remedy Plan Therapeutics Announces Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
bottom of page